- Home
- GDO vs HRTX Comparison
GDO vs HRTX Comparison
Compare GDO & HRTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- GDO
- HRTX
- Stock Information
- Founded
- GDO 2009
- HRTX 1983
- Country
- GDO United States
- HRTX United States
- Employees
- GDO N/A
- HRTX N/A
- Industry
- GDO Finance Companies
- HRTX Biotechnology: Pharmaceutical Preparations
- Sector
- GDO Finance
- HRTX Health Care
- Exchange
- GDO Nasdaq
- HRTX Nasdaq
- Market Cap
- GDO 182.8M
- HRTX 180.5M
- IPO Year
- GDO N/A
- HRTX 1987
- Fundamental
- Price
- GDO $11.68
- HRTX $1.19
- Analyst Decision
- GDO
- HRTX Strong Buy
- Analyst Count
- GDO 0
- HRTX 3
- Target Price
- GDO N/A
- HRTX $5.67
- AVG Volume (30 Days)
- GDO 39.4K
- HRTX 2.0M
- Earning Date
- GDO 01-01-0001
- HRTX 11-12-2024
- Dividend Yield
- GDO 9.81%
- HRTX N/A
- EPS Growth
- GDO N/A
- HRTX N/A
- EPS
- GDO N/A
- HRTX N/A
- Revenue
- GDO N/A
- HRTX $137,737,000.00
- Revenue This Year
- GDO N/A
- HRTX $19.15
- Revenue Next Year
- GDO N/A
- HRTX $21.29
- P/E Ratio
- GDO N/A
- HRTX N/A
- Revenue Growth
- GDO N/A
- HRTX 12.13
- 52 Week Low
- GDO $11.21
- HRTX $0.87
- 52 Week High
- GDO $13.04
- HRTX $3.93
- Technical
- Relative Strength Index (RSI)
- GDO 28.18
- HRTX 25.49
- Support Level
- GDO $11.81
- HRTX $1.04
- Resistance Level
- GDO $11.99
- HRTX $1.90
- Average True Range (ATR)
- GDO 0.11
- HRTX 0.13
- MACD
- GDO 0.01
- HRTX -0.06
- Stochastic Oscillator
- GDO 5.88
- HRTX 17.44
About GDO Western Asset Global Corporate Defined Opportunity Fund Inc.
Western Asset Global Corp Defined Opp is a closed-end management investment company with a primary investment objective to provide current income. Its secondary objective is to seek capital appreciation. The Fund invests in the United States and foreign corporate fixed-income securities of varying maturities.
About HRTX Heron Therapeutics Inc.
Heron Therapeutics Inc is a commercial-stage biotechnology company. It is focused on improving the lives of patients by developing treatments that address some of the unmet patient needs. The company's product portfolio consists of APONVIE, SUSTOL, ZYNRELEF, and CINVANTI.